Jaroslav Hajek

Ostrava, MO, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Journal: The New England journal of medicine
Published: April 17, 2024

Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.

Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.

Journal: The oncologist
Published: June 12, 2023

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology
Published: April 13, 2022

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology
Published: February 10, 2022

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Journal: The New England journal of medicine
Published: August 18, 2021

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors.

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors.

Journal: In vivo (Athens, Greece)
Published: June 08, 2021

Is there an intermediate-risk non-seminoma? long-term treatment results from a single center.

Is there an intermediate-risk non-seminoma? long-term treatment results from a single center.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Published: September 28, 2014

Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma

Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: April 24, 2013
Showing 1-8 of 8

Last Updated: 09/26/2026